Discovery of novel 2,4-diarylaminopyrimidine hydrazone derivatives as potent anti-thyroid cancer agents capable of inhibiting FAK
Hongting Li, Mei-Qi Jia, Zhao-Long Qin, Changliang Lu, Weili Chu, Ze Zhang, Jinbo Niu, Jian Song, Sai-Yang Zhang, Lijun Fu · 2024
Read Discovery of novel 2,4-diarylaminopyrimidine hydrazone derivatives as potent anti-thyroid cancer agents capable of inhibiting FAK by Hongting Li, Mei-Qi Jia, Zhao-Long Qin, Changliang Lu, Weili Chu, Ze Zhang, Jinbo Niu, Jian Song, Sai-Yang Zhang, Lijun Fu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11578424.txt.
Description
Hongting Li and co-authors design a family of drug candidates against thyroid cancer in a 2024 paper. Thirty new compounds built on a pyrimidine-hydrazone frame were synthesized and tested on a thyroid cancer cell line that overproduces the signaling protein FAK, a driver of growth and spread.
Most compounds killed the cells at low doses. The best, labeled 14f, stopped cell growth at a tenth of a micromolar and blocked FAK at nanomolar strength. Computer studies showed it fits the target well with favorable drug-like properties. It switched off FAK's activation marks without lowering the protein itself, and slowed both growth and migration of the cancer cells. The authors present the series as a promising start for FAK-targeted thyroid cancer drugs.
Catalog record
| CREATOR | Hongting Li, Mei-Qi Jia, Zhao-Long Qin, Changliang Lu, Weili Chu, Ze Zhang, Jinbo Niu, Jian Song, Sai-Yang Zhang, Lijun Fu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |